Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD

Why It Matters

Without universal molecular testing, patients risk receiving suboptimal first‑line regimens, which can diminish survival and increase healthcare costs. Closing the testing gap is critical for delivering precision oncology at scale.

Key Takeaways

• Testing rates for advanced NSCLC now near 70% nationally
• Reflex testing cuts result turnaround to 7‑10 days
• Community clinics lag due to missing reflex protocols
• Delayed molecular results risk suboptimal first‑line therapy
• Nurse navigators improve testing completion rates

Pulse Analysis

The surge toward universal molecular profiling in advanced non‑small cell lung cancer reflects a broader shift toward precision medicine. As targeted therapies expand, guidelines from bodies like NCCN and ASCO now mandate comprehensive genomic assessment before initiating first‑line treatment. This push has lifted testing prevalence from roughly half of patients a few years ago to nearly seven in ten today, promising more accurate matching of drugs to driver mutations such as EGFR, ALK, and KRAS.

Despite the upward trend, systemic barriers keep true universality out of reach. In many community hospitals, biopsies are still ordered without reflex molecular panels, requiring a separate request from the oncologist—a step that introduces delays and potential omissions. Academic centers benefit from integrated pathways where pathologists automatically trigger next‑generation sequencing, delivering results within a week. The disparity underscores the importance of standardizing reflex protocols, investing in pathology infrastructure, and embedding nurse navigators who can shepherd specimens through the diagnostic cascade.

The clinical stakes are high: delayed or absent molecular data can force clinicians to start empiric chemotherapy, missing the chance to deploy a more effective targeted agent. This not only impacts patient outcomes but also inflates costs through less efficient treatment courses. Health systems aiming to close the gap should prioritize reflex testing mandates, expand multidisciplinary tumor boards, and leverage tele‑pathology to extend academic‑level capabilities to community settings. As reimbursement models evolve to reward value‑based care, universal molecular testing will likely become a quality metric tied to reimbursement, accelerating its adoption across the oncology landscape.